The Second EBMT-China Scientific Forum
第二届EBMT-中国科学论坛

Friday, 18 November 2022
2022年11月18日，周五

Venue: Tianjin Conrad Hotel (No. 46, Tianta Road, Nankai District, Tianjin)
地点：天津康莱德酒店（天津市南开区天塔道46号）

Organisers: Institute of Hematology & Blood Diseases Hospital,
Chinese Academy of Medical Sciences, Peking Union Medical College
EBMT Foundation Shanghai Office

主办方：中国医学科学院血液病医院（中国医学科学院血液学研究所）
欧洲血液和骨髓移植协会（荷兰）基金会上海代表处
Dear Distinguished Experts and Professors:

It is our great honour to invite you to attend "the Second EBMT-China Scientific Forum" jointly hosted by Institute of Haematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College and the EBMT Foundation Shanghai Office.

This in-person and online event aims to provide a platform for academic exchange and mutual learning by pooling insights and novel ideas from world-class experts and scholars in the fields of haematology and blood and marrow transplantation from China and Europe. The forum will serve to enhance innovation and communication on new treatments and therapies, as well as promote discussions of cutting-edge clinical research results in the aforementioned fields between China and Europe, with the pursuit of initiating clinical-demand-oriented multi-center research cooperation. Specifically, this forum, themed "Acute Leukaemia", highlights discussions on concerning topics such as Chemotherapy in AML and the latest developments in Emerging Drugs, MRD Guides AML Treatment Choices, Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for AML and more. Participants will have the opportunity to draw on novel research outcomes and updated development results in the fields.

The forum is scheduled for 18 November 2022 and will be held onsite in Tianjin and online. We are looking forward to your esteemed presence, either in-person or virtually, at this academic feast!

Dr. Jack Li


尊敬的专家教授：

我们十分荣幸地邀请您参加由中国医学科学院血液病医院（中国医学科学院血液学研究所）和欧洲血液和骨髓移植协会（荷兰）基金会上海代表处共同主办的“第二届EBMT-中国科学论坛”。

本次论坛采用线上线下相结合的方式，旨在为国内外血液和骨髓移植领域的顶级专家学者们提供交流互鉴的平台，促进中欧在血液和骨髓移植领域新药物和新疗法的创新与交流、前沿临床研究成果的分享与探讨，以临床需求为导向，启动多中心研究合作。本届论坛主题为“急性白血病”，将围绕AML化疗及新型药物进展、MRD指导AML治疗选择、AML的自体和异基因造血干细胞移植等课题进行深入探讨和洞见分享。

本次论坛将于2022年11月18日在天津召开。我们诚挚期待您参与这场学术盛宴！

Dr. Jack Li

Prof. Nicolaus Kräger
President(Europe)

科罗格 教授

Prof. Norbert Claude Guirguis
President(Europe)

高汉 教授

Prof. Anna Sureda
President(Europe)

苏英达 教授

Prof. Jianxiang WANG
President(China)

王建祥 教授

Prof. Erfle JiANG
Executive President

姜尔烈 教授
The Second EBMT-China Scientific Forum
第二届EBMT－中国科学论坛

Organisers:
Institute of Hematology & Blood Diseases Hospital,
Chinese Academy of Medical Sciences, Peking Union Medical College
EBMT Foundation Shanghai Office

主办方：
中国医学科学院血液病医院（中国医学科学院血液学研究所）
欧洲血液和骨髓移植协会（荷兰）基金会上海代表处

Friday, 18 November 2022, Tianjin
2022年11月18日，周五，天津
15:00-19:00 (8:00-12:30 CET)

(8:00-8:30 CET) Opening Ceremony
15:00-15:30 开幕式

Tao CHENG, Director of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
程涛，中国医学科学院血液病医院（中国医学科学院血液学研究所）所院长

Jianxiang WANG, Associate Director of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
王建祥，中国医学科学院血液病医院（中国医学科学院血液学研究所）副院长

Anna SUREDA, President of EBMT
苏芮达，EBMT主席

Norbert Claude GORIN, Chief Representative of EBMT Foundation Shanghai Office
高汉，欧洲血液和骨髓移植协会（荷兰）基金会上海代表处首席代表

Representative from Science and Technology Commission of Tianjin Municipality
天津市科技局领导
### Session 1

**Moderators:** Anna SUREDA, Junren CHEN

**Presenter:** 

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Organisation</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30-15:50</td>
<td>Yu ZHANG</td>
<td>Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong</td>
<td>Chemotherapy in AML and Latest Developments in Emerging Drugs of AML and MDS-related Myeloid Disorders</td>
</tr>
<tr>
<td>15:55-16:15</td>
<td>Jorge SIERRA</td>
<td>Hospitalet de Santa Creu i Sant Pau, Barcelona</td>
<td>European Classification and Treatment Recommendations (ELN) of AML and MDS-related Myeloid Disorders</td>
</tr>
<tr>
<td>16:15-16:30</td>
<td>DISCUSSION</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Session 2

**Moderators:** Norbert Claude GORIN, XI ZHANG

**Presenter:** 

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Organisation</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:20-16:40</td>
<td>Yinguo CHANG</td>
<td>Peking University, Institute of Pathology, Beijing</td>
<td>Role of MRD pro and post transplantation in AML: European Experience and CRPDEAML Association’s Point of View</td>
</tr>
<tr>
<td>16:40-17:00</td>
<td>Michael Hauser</td>
<td>Hannover Medical School, Germany</td>
<td>Role of MRD pro and post transplantation in AML: European Experience and CRPDEAML Association’s Point of View</td>
</tr>
<tr>
<td>17:00-17:15</td>
<td>DISCUSSION</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Session 3

**Moderators:** Nikolaus KRÖGER, Xiaowen TANG

**Presenter:**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Organisation</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30-16:50</td>
<td>Eda JANG</td>
<td>Institute of Hematology &amp; Blood Disease Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing</td>
<td>Autologous Hematopoietic Stem Cell Transplantation for AML: AML Cell line data and chordoma malignant bone tumor</td>
</tr>
<tr>
<td>16:50-17:10</td>
<td>Norbert Claude GORIN</td>
<td>Hospital St. Antoine, Paris</td>
<td>Autologous hematopoietic stem cell transplantation for AML: European Experience and CRPDEAML Association’s Point of View</td>
</tr>
<tr>
<td>17:10-17:25</td>
<td>DISCUSSION</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Session 4

**Moderators:** Raffaella Greco, Hui WEI

**Presenter:**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Organisation</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:10-18:30</td>
<td>Yanmin ZHAO</td>
<td>First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang</td>
<td>Allogeneic Hematopoietic Stem Cell Transplantation for AML: European Experience and CRPDEAML Association’s Point of View</td>
</tr>
<tr>
<td>18:30-18:50</td>
<td>Charles Craddock</td>
<td>Centre for Clinical Hematology, Queen Elizabeth Hospital, Birmingham, UK</td>
<td>Allogeneic Hematopoietic Stem Cell Transplantation for AML: European Experience and CRPDEAML Association’s Point of View</td>
</tr>
<tr>
<td>18:50-19:10</td>
<td>DISCUSSION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:10-19:30</td>
<td>Lei GAO</td>
<td>Xinhua Hospital, Changsha</td>
<td>Strategies to Prevent and Treat Post-transplant Relapse in High-risk AML</td>
</tr>
<tr>
<td>19:30-19:50</td>
<td>DISCUSSION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:50-20:10</td>
<td>Clare Horgan</td>
<td>EBMT Training Committee</td>
<td>Introduction to the EBMT Training Committee</td>
</tr>
<tr>
<td>20:10-20:30</td>
<td>EBMT</td>
<td>EBMT Training Committee</td>
<td>Introduction to the EBMT Training Committee</td>
</tr>
</tbody>
</table>

*(12:10-12:30 CET) Closing Ceremony: Nikolaus Kröger, Elrie JANG*